Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Closure of Trading Window
Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading by Designated Persons we would like to inform you that, inter alia, for the purpose of declaration of financial results of the Company, for the year ending 31st December 2021, the trading window of the Company shall remain closed from 1st January 2022 till 48 hours after the announcement of the results to the stock exchanges. Kindly take the above information on record. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.
Sanofi to buy US biotech firm Amunix for $1 billion
Immuno-oncology firm Amunix is developing cancer therapies based on cytokines -- small proteins that play a role in controlling the immune system -- and T-cells, a type of white blood cell.
Sanofi, Glaxo Covid shot works as booster, but release pushed back
Sanofi shares dropped less than 1% in Paris trading, as did Glaxo in London
Sanofi, GSK say Covid-19 vaccine booster candidate give good immune response
Sanofi, GSK say a single booster dose of their Covid-19 vaccine candidate provided strong immune responses, preliminary data from clinical trials show. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed.
Encube to buy anti-microbial brand Soframycin from Sanofi for Rs 125 cr
Will also acquire other legacy associated brands such as Sofradex (antibacterial cream), Sofracort (eye and ear drops), Soframycin-Tulle (cream) for India and Sri Lanka markets